Status:

UNKNOWN

Spastic Cocontractions and Limitation of Active Movements Before and After Treatment During Injection of Botulinum Toxin

Lead Sponsor:

University Hospital, Toulouse

Conditions:

Cerebrovascular Accident

Stroke

Eligibility:

All Genders

18+ years

Brief Summary

Following a stroke , 55% of the patients do not recover any traction of the upper limb and 30% a residual motricity not allowing a functional grip. For this last group of patients, there are major the...

Detailed Description

Descriptive study of spastic cocontraction index before and after botulinum toxin A injections during active elbow extension in chronic vascular hemiplegic patients. The spastic cocontraction score w...

Eligibility Criteria

Inclusion

  • Having notified his non-opposition to participate in the search
  • Ischemic or hemorrhagic stroke of more than 6 months, cortical and / or subcortical;
  • Indication to the realization of an injection of Botulinum Toxin A in the flexor muscles of the elbow according to the usual clinical criteria: presence of a functional complaint or aesthetic expressed by the patient and related to hyperactivity muscular (spasticity or cocontraction) on the flexor muscles elbow, which is a focal treatment by injection of botulinum toxin;
  • Possibility of active extension of elbow\> 20 °;
  • Patients naive to Botulinum Toxin A or more than 4 months of a first injection of Botulinum Toxin A, having targeted the elbow flexors.

Exclusion

  • Passive limitation of elbow extension\> 30 °;
  • Pain when performing active movements of flexion / extension of the elbow
  • Cognitive impairment limiting the comprehension of three basic instructions (proof test of the 3 papers of the MMS);
  • Evolutionary or decompensated neurological pathology; Ischemic or haemorrhagic stroke of less than 6 months;
  • General contraindication to the production of botulinum toxin; history of myasthenia gravis, Lambert Eaton syndrome; history of neuromuscular disease; surgery with curarization for less than 1 month; treatment with aminoglycoside, aminoquinoline or cyclosporine
  • Legal incapacity (safeguard of justice, guardianship).

Key Trial Info

Start Date :

January 14 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 1 2019

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT03453008

Start Date

January 14 2018

End Date

September 1 2019

Last Update

March 5 2018

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital Toulouse

Toulouse, France, 31052